Transfusion-related acute lung injury (TRALI) after convalescent plasma therapy in COVID-19 patient

Abstract

The coronavirus disease 2019 (COVID-19) continues to spread all around the world. Mortality and morbidity rates are increasing-up to now. Although convalescent plasma therapy can be thought to be useful in the treatment of COVID-19, it carries potential risks, such as transfusion-related acute lung injury (TRALI). In COVID-19 infection, tachypnea, tachycardia, increased need for oxygenation, and the presence of bilateral widespread infiltrates on radiological imagings are evaluated as acute respiratory distress syndrome (ARDS). This clinical situation may develop independently from disease progression in patients receiving convalescent plasma therapy and it is called TRALI. We aimed to present our case to discuss the difficulty of this situation to differentiate from COVID-19 related ARDS.